Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 117-129

  Imai, Y ^a   Dobrian, A D ^a   Weaver, J R ^a   Butcher, M J ^a   Cole, B K ^a   Galkina, E V ^a   Morris, M A ^a   Taylor Fishwick, D A ^a   Nadler, J L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

12 lipoxygenase; 15 lipoxygenase; Interleukin 12; Interleukin 17A; NADPH oxidase 1

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 17; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL LOSS; DIABETES MELLITUS; HYPERGLYCEMIA; INFLAMMATION; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; VASCULAR DISEASE;

12-LIPOXYGENASE; 15-LIPOXYGENASE; INTERLEUKIN-12; INTERLEUKIN-17A; NADPH OXIDASE-1;

ADIPOSE TISSUE; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MICE; VASCULAR DISEASES;

EID: 84883511924     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12161     Document Type: Review

References (74)

1. Das A, Mukhopadhyay S. The evil axis of obesity, inflammation and type-2 diabetes. Endocr Metab Immune Disord Drug Targets 2011; 11: 23-31.
2. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-197.
3. Imai Y, Dobrian AD, Morris MA, Nadler JL. Islet inflammation: a unifying target for diabetes treatment? Trends Endocrinol Metab 2013; 24: 351-360.
4. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, Nadler JL. Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 2011; 50: 115-131.
5. Jisaka M, Kim RB, Boeglin WE, Brash AR. Identification of amino acid determinants of the positional specificity of mouse 8S-lipoxygenase and human 15S-lipoxygenase-2. J Biol Chem 2000; 275: 1287-1293.
6. Cole BK, Lieb DC, Dobrian AD, Nadler JL. 12- and 15-lipoxygenases in adipose tissue inflammation. Prostaglandins Other Lipid Mediat 2013; 104-105: 84-92.
7. Kuhn H, Borngraber S. Mammalian 15-lipoxygenases. Enzymatic properties and biological implications. Adv Exp Med Biol 1999; 447: 5-28.
8. Kuhn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002; 68-69: 263-290.
9. Nunemaker CS, Chen M, Pei H et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am J Physiol Endocrinol Metab 2008; 295: E1065-E1075.
10. Sears DD, Miles PD, Chapman J et al. 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009; 4: e7250.
11. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 2009; 17: 1657-1663.
12. Chakrabarti SK, Wen Y, Dobrian AD et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 2011; 300: E175-E187.
13. Boden G. Endoplasmic reticulum stress: another link between obesity and insulin resistance/inflammation? Diabetes 2009; 58: 518-519.
14. Cole BK, Kuhn NS, Green-Mitchell SM et al. 12/15-Lipoxygenase signaling in the endoplasmic reticulum stress response. Am J Physiol Endocrinol Metab 2012; 302: E654-E665.
15. Cole BK, Morris MA, Grzesik WJ, Leone KA, Nadler JL. Adipose tissue-specific deletion of 12/15-lipoxygenase protects mice from the consequences of a high-fat diet. Mediators Inflamm 2012; 2012: 851798.
16. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55: 715-721.
17. Serhan CN, Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008; 153(Suppl. 1): S200-S215.
18. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-361.
19. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3: 279-312.
20. Serhan CN, Yang R, Martinod K et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15-23.
21. Chiang N, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 163-177.
22. Titos E, Rius B, Gonzalez-Periz A et al. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 187: 5408-5418.
23. Uderhardt S, Herrmann M, Oskolkova OV et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012; 36: 834-846.
24. Lundbom J, Heikkinen S, Fielding B, Hakkarainen A, Taskinen MR, Lundbom N. PRESS echo time behavior of triglyceride resonances at 1.5T: detecting omega-3 fatty acids in adipose tissue in vivo. J Magn Reson 2009; 201: 39-47.
25. Gonzalez-Periz A, Horrillo R, Ferre N et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23: 1946-1957.
26. Dobrian AD, Lieb DC, Ma Q et al. Differential expression and localization of 12/15 lipoxygenases in adipose tissue in human obese subjects. Biochem Biophys Res Commun 2010; 403: 485-490.
27. Kim JA, Gu JL, Natarajan R, Berliner JA, Nadler JL. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 1995; 15: 942-948.
28. Chen XS, Funk CD. Structure-function properties of human platelet 12-lipoxygenase: chimeric enzyme and in vitro mutagenesis studies. FASEB J 1993; 7: 694-701.
29. Gealekman O, Guseva N, Hartigan C et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011; 123: 186-194.
30. Claria J, Nguyen BT, Madenci A, Ozaki CK, Serhan CN. Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol 2013; 304: C1141-1149.
31. Taylor-Fishwick DA, Weaver JR, Grzesik W et al. Production and function of IL-12 in islets and beta cells. Diabetologia 2013; 56: 126-135.
32. Weaver JR, Holman TR, Imai Y et al. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endocrinol 2012; 358: 88-95.
33. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 12-Lipoxygenase products reduce insulin secretion and {beta}-cell viability in human islets. J Clin Endocrinol Metab 2010; 95: 887-893.
34. Kenyon V, Rai G, Jadhav A et al. Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase. J Med Chem 2011; 54: 5485-5497.
35. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest 1999; 103: 1431-1436.
36. McDuffie M, Maybee NA, Keller SR et al. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 2008; 57: 199-208.
37. Green-Mitchell SM, Tersey SA, Cole BK et al. Deletion of 12/15-lipoxygenase alters macrophage and islet function in NOD-alox15(null) mice, leading to protection against type 1 diabetes development. PLoS One 2013; 8: e56763.
38. Tersey SA, Nishiki Y, Templin AT et al. Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 2012; 61: 818-827.
39. Laybutt DR, Sharma A, Sgroi DC, Gaudet J, Bonner-Weir S, Weir GC. Genetic regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J Biol Chem 2002; 277: 10912-10921.
40. Tokuyama Y, Sturis J, DePaoli AM et al. Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 1995; 44: 1447-1457.
41. Igoillo-Esteve M, Marselli L, Cunha DA et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 2010; 53: 1395-1405.
42. Hanley SC, Austin E, Assouline-Thomas B et al. {beta}-Cell mass dynamics and islet cell plasticity in human type 2 diabetes. Endocrinology 2010; 151: 1462-1472.
43. Herrera PL, Nepote V, Delacour A. Pancreatic cell lineage analyses in mice. Endocrine 2002; 19: 267-278.
44. Katsuta H, Akashi T, Katsuta R et al. Single pancreatic beta cells co-express multiple islet hormone genes in mice. Diabetologia 2010; 53: 128-138.
45. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 2012; 150: 1223-1234.
46. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008; 36: 343-347.
47. Modak MA, Parab PB, Ghaskadbi SS. Pancreatic islets are very poor in rectifying oxidative DNA damage. Pancreas 2009; 38: 23-29.
48. Michalska M, Wolf G, Walther R, Newsholme P. Effects of pharmacological inhibition of NADPH oxidase or iNOS on pro-inflammatory cytokine, palmitic acid or H2O2-induced mouse islet or clonal pancreatic beta-cell dysfunction. Biosci Rep 2010; 30: 445-453.
49. Janciauskiene S, Ahren B. Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 2000; 267: 619-625.
50. Morgan D, Oliveira-Emilio HR, Keane D et al. Glucose, palmitate and pro-inflammatory cytokines modulate production and activity of a phagocyte-like NADPH oxidase in rat pancreatic islets and a clonal beta cell line. Diabetologia 2007; 50: 359-369.
51. Nakayama M, Inoguchi T, Sonta T et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 2005; 332: 927-933.
52. Oliveira HR, Verlengia R, Carvalho CR, Britto LR, Curi R, Carpinelli AR. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 2003; 52: 1457-1463.
53. Uchizono Y, Takeya R, Iwase M et al. Expression of isoforms of NADPH oxidase components in rat pancreatic islets. Life Sci 2006; 80: 133-139.
54. Cunningham GA, McClenaghan NH, Flatt PR, Newsholme P. L-Alanine induces changes in metabolic and signal transduction gene expression in a clonal rat pancreatic beta-cell line and protects from pro-inflammatory cytokine-induced apoptosis. Clin Sci (Lond) 2005; 109: 447-455.
55. Inoguchi T, Nawata H. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome. Curr Drug Targets 2005; 6: 495-501.
56. Newsholme P, Haber EP, Hirabara SM et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583: 9-24.
57. Volchuk A, Ron D. The endoplasmic reticulum stress response in the pancreatic beta-cell. Diabetes Obes Metab 2010; 12(Suppl. 2): 48-57.
58. Matti A, Kyathanahalli C, Kowluru A. Protein farnesylation is requisite for mitochondrial fuel-induced insulin release: further evidence to link reactive oxygen species generation to insulin secretion in pancreatic beta-cells. Islets 2012; 4: 74-77.
59. Syed I, Kyathanahalli CN, Jayaram B et al. Increased phagocyte-like NADPH oxidase and ROS generation in type 2 diabetic ZDF rat and human islets: role of Rac1-JNK1/2 signaling pathway in mitochondrial dysregulation in the diabetic islet. Diabetes 2011; 60: 2843-2852.
60. Syed I, Kyathanahalli CN, Kowluru A. Phagocyte-like NADPH oxidase generates ROS in INS 832/13 cells and rat islets: role of protein prenylation. Am J Physiol Regul Integr Comp Physiol 2011; 300: R756-R762.
61. Jiao J, Dou L, Li M et al. NADPH oxidase 2 plays a critical role in dysfunction and apoptosis of pancreatic beta-cells induced by very low-density lipoprotein. Mol Cell Biochem 2012; 370: 103-113.
62. Yuan H, Zhang X, Huang X et al. NADPH oxidase 2-derived reactive oxygen species mediate FFAs-induced dysfunction and apoptosis of beta-cells via JNK, p38 MAPK and p53 pathways. PLoS One 2010; 5: e15726.
63. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
64. Weaver JR, Taylor-Fishwick DA. Regulation of NOX-1 expression in beta cells: a positive feedback loop involving the Src-kinase signaling pathway. Mol Cell Endocrinol 2013; 369: 35-41.
65. Yang Z, Chen M, Ellett JD et al. Autoimmune diabetes is blocked in Stat4-deficient mice. J Autoimmun 2004; 22: 191-200.
66. Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas 2003; 26: e99-e104.
67. Rong S, Cao Q, Liu M et al. Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis. J Lipid Res 2012; 53: 686-695.
68. Burdon KP, Rudock ME, Lehtinen AB et al. Human lipoxygenase pathway gene variation and association with markers of subclinical atherosclerosis in the diabetes heart study. Mediators Inflamm 2010; 2010: 170153.
69. Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost 2011; 106: 787-795.
70. Jagannathan-Bogdan M, McDonnell ME, Shin H et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 2011; 186: 1162-1172.
71. Ohshima K, Mogi M, Jing F et al. Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance. Hypertension 2012; 59: 493-499.
72. Madhur MS, Lob HE, McCann LA et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-507.
73. Butcher MJ, Gjurich BN, Phillips T, Galkina EV. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 2012; 110: 675-687.
74. Kenyon V, Chorny I, Carvajal WJ, Holman TR, Jacobson MP. Novel human lipoxygenase inhibitors discovered using virtual screening with homology models. J Med Chem 2006; 49: 1356-1363.